… (a shortened, rapid course) can be attempted followed by systemic therapy vs upfront systemic
therapy. Systemic therapy in patients with BRAF V600E mutations should begin with the …

… or systemic therapy. The ORR and DCR were 0 and 40%, while median PFS and OS
were 2.8 (CI 0.7–5.6) and 5.0 months (CI 0.7–5.7) [44]. The most frequent AEs were palmar-plantar …

… an intriguing treatment option, as restoring sensitivity to RAI can minimize time that patients
receive other systemic therapies and spare patients troublesome side effects and expense. …

… We searched for all cases of ATC in our institutional prospective thyroid cancer database
from 2004 to 2011. Patients were only included into the study when they had histologically …

… is crucial for appropriate direction of systemic therapy in advanced thyroid cancer [9, 28]. …
The decision to initiate systemic therapy with TKIs should not be made solely on the basis of …

… systemic therapies. Moreover, the extremely rapid disease evolution makes the criteria for
entering the protocol often prohibitive, thus further restricting patient inclusion. This, apart from …

… the relationship between serum TSH and prognostic indicators for thyroid cancer. Eligibility
for this analysis was extended to include thyroid cancer series (ie without controls) to ensure …

… Systemic therapy for thyroid carcinoma represents an option only in the presence of
recurrent/metastatic disease, not iodine avid, not more suitable for palliative surgery, RT, …

… thyroid cancer (DTC) and medullary thyroid carcinoma (MTC) would progress to advanced
stages of thyroid cancer. … and safety of peptide receptor radionuclide therapy (PRRT) in the …

… thyroid cancer burden, this review will focus on its management. Since PTC and FTC are often
treated with similar therapy, we will collectively refer to this group of cancers … treat systemic …